FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567586164> ?p ?o ?g. }

• W2567586164 abstract "Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine and is pathologically associated with several types of cancer. We identified oxMIF, an immunological and conformationally distinct isoform of MIF that can be mimicked in vitro by mild oxidation of recombinant MIF. Fully human monoclonal antibodies that specifically target oxMIF were shown to inhibit signaling pathways associated with tumor proliferation and progression in vitro and in vivo in syngeneic or xenogeneic animal models. To evaluate the use of oxMIF as a biomarker of malignant tissue, we acquired plasma and tumor tissues from patients with colorectal cancer (CRC), ovarian, and non-small cell lung cancer (NSCLC), as well as control plasma and control tissue from healthy donors, i.e. in a normal state of health, with no apparent signs of disease. We developed a novel immunohistochemistry (IHC) method to detect oxMIF in malignant tissues and used a specific new ELISA to detect oxMIF in plasma. In patients with CRC, we detected oxMIF by IHC in primary tumors (31 of 39) and in liver, lung and lymph-node metastases (n = 10). Staining intensities showed variation between different tumor cells, as well as in the microenvironment. Similarly, we detected oxMIF by IHC in most types of ovarian cancer (n = 42), but not in controls (n = 4), and observed some variations in the localization and intensities of staining. We also detected oxMIF in liver metastases from patients with ovarian cancer (n = 2). In patients with NSCLC (n = 32), 22 samples showed a strong staining for oxMIF. In tissues from healthy donors (4 colon, 4 ovary and 3 lung), oxMIF was not or barely detectable, whereas total MIF (sum of reduced and oxidized MIF) was widely expressed in normal and tumor tissues and showed a more diffuse spatial distribution than oxMIF. In commercially acquired plasma samples from patients with CRC (n = 46) and NSCLC (n = 15), we did not observe a significant increase of oxMIF levels (median = 0 for both) compared with the plasma from healthy donors (median = 0; n = 69). In patients with ovarian cancer, significant increased levels of oxMIF were measured in plasma (median = 3.5ng/mL, n = 42), and more specifically from patients with papillary serous cystadenocarcinoma or serous cystadenocarcinoma compared with clear cell adenocarcinoma (medians = 3.5, 4.0, and 0 ng/mL respectively). Our studies demonstrated that oxMIF is a disease-related isoform of MIF that can be specifically detected in tissues from various types of cancer. We therefore suggest that oxMIF reflects a new biomarker in solid tumors and has potential diagnostic and prognostic value. A phase 1 clinical study of a novel human antibody that selectively targets oxMIF is currently ongoing in patients with solid malignancies (ClinicalTrials.gov identifier: NCT01765790). Citation Format: Nicolas Sabarth, Dirk Volkel, Michael Thiele, Alexander Schinagl, Patrice Douillard, Friedrich Scheiflinger, Randolf Kerschbaumer. Cancerous tissue can be identified by the presence of oxMIF, the oxidized form of macrophage migration inhibitory factor. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3385. doi:10.1158/1538-7445.AM2015-3385" @default.
• W2567586164 created "2017-01-06" @default.
• W2567586164 creator A5012717738 @default.
• W2567586164 creator A5042240968 @default.
• W2567586164 creator A5045242452 @default.
• W2567586164 creator A5080659084 @default.
• W2567586164 creator A5087143585 @default.
• W2567586164 creator A5089410333 @default.
• W2567586164 creator A5091504293 @default.
• W2567586164 date "2015-08-01" @default.
• W2567586164 modified "2023-09-22" @default.
• W2567586164 title "Abstract 3385: Cancerous tissue can be identified by the presence of oxMIF, the oxidized form of macrophage migration inhibitory factor" @default.
• W2567586164 doi "https://doi.org/10.1158/1538-7445.am2015-3385" @default.
• W2567586164 hasPublicationYear "2015" @default.
• W2567586164 type Work @default.
• W2567586164 sameAs 2567586164 @default.
• W2567586164 citedByCount "0" @default.
• W2567586164 crossrefType "proceedings-article" @default.
• W2567586164 hasAuthorship W2567586164A5012717738 @default.
• W2567586164 hasAuthorship W2567586164A5042240968 @default.
• W2567586164 hasAuthorship W2567586164A5045242452 @default.
• W2567586164 hasAuthorship W2567586164A5080659084 @default.
• W2567586164 hasAuthorship W2567586164A5087143585 @default.
• W2567586164 hasAuthorship W2567586164A5089410333 @default.
• W2567586164 hasAuthorship W2567586164A5091504293 @default.
• W2567586164 hasConcept C104177226 @default.
• W2567586164 hasConcept C121608353 @default.
• W2567586164 hasConcept C126322002 @default.
• W2567586164 hasConcept C142724271 @default.
• W2567586164 hasConcept C203014093 @default.
• W2567586164 hasConcept C204232928 @default.
• W2567586164 hasConcept C2776256026 @default.
• W2567586164 hasConcept C2778690821 @default.
• W2567586164 hasConcept C2780427987 @default.
• W2567586164 hasConcept C2780849966 @default.
• W2567586164 hasConcept C2781197716 @default.
• W2567586164 hasConcept C502942594 @default.
• W2567586164 hasConcept C526805850 @default.
• W2567586164 hasConcept C55493867 @default.
• W2567586164 hasConcept C71924100 @default.
• W2567586164 hasConcept C86803240 @default.
• W2567586164 hasConceptScore W2567586164C104177226 @default.
• W2567586164 hasConceptScore W2567586164C121608353 @default.
• W2567586164 hasConceptScore W2567586164C126322002 @default.
• W2567586164 hasConceptScore W2567586164C142724271 @default.
• W2567586164 hasConceptScore W2567586164C203014093 @default.
• W2567586164 hasConceptScore W2567586164C204232928 @default.
• W2567586164 hasConceptScore W2567586164C2776256026 @default.
• W2567586164 hasConceptScore W2567586164C2778690821 @default.
• W2567586164 hasConceptScore W2567586164C2780427987 @default.
• W2567586164 hasConceptScore W2567586164C2780849966 @default.
• W2567586164 hasConceptScore W2567586164C2781197716 @default.
• W2567586164 hasConceptScore W2567586164C502942594 @default.
• W2567586164 hasConceptScore W2567586164C526805850 @default.
• W2567586164 hasConceptScore W2567586164C55493867 @default.
• W2567586164 hasConceptScore W2567586164C71924100 @default.
• W2567586164 hasConceptScore W2567586164C86803240 @default.
• W2567586164 hasLocation W25675861641 @default.
• W2567586164 hasOpenAccess W2567586164 @default.
• W2567586164 hasPrimaryLocation W25675861641 @default.
• W2567586164 hasRelatedWork W1971336947 @default.
• W2567586164 hasRelatedWork W1976071844 @default.
• W2567586164 hasRelatedWork W2045458906 @default.
• W2567586164 hasRelatedWork W2079653046 @default.
• W2567586164 hasRelatedWork W2329150630 @default.
• W2567586164 hasRelatedWork W2330318183 @default.
• W2567586164 hasRelatedWork W2348205642 @default.
• W2567586164 hasRelatedWork W2366122705 @default.
• W2567586164 hasRelatedWork W2366980834 @default.
• W2567586164 hasRelatedWork W2379554630 @default.
• W2567586164 hasRelatedWork W2382402114 @default.
• W2567586164 hasRelatedWork W2389922708 @default.
• W2567586164 hasRelatedWork W2625357296 @default.
• W2567586164 hasRelatedWork W2729171328 @default.
• W2567586164 hasRelatedWork W2792444099 @default.
• W2567586164 hasRelatedWork W2980266439 @default.
• W2567586164 hasRelatedWork W301941148 @default.
• W2567586164 hasRelatedWork W3029993918 @default.
• W2567586164 hasRelatedWork W3151618738 @default.
• W2567586164 hasRelatedWork W3165045125 @default.
• W2567586164 isParatext "false" @default.
• W2567586164 isRetracted "false" @default.
• W2567586164 magId "2567586164" @default.
• W2567586164 workType "article" @default.